- Hormone
- Growth Factor
- Cytokines
- Enzymes
- Others
Recombinant Proteins Market size was valued at USD 1,926.1 million in 2022 and is projected to grow at a 3.1% CAGR from 2023 to 2029. Proteins encoded by a gene (recombinant DNA) and cloned in a prokaryotic system are known as prokaryotic recombinant proteins (E.coli). Prokaryotic recombinant proteins are good candidates for chronic treatments and numerous autoimmune illnesses due to their high specificity and low immunogenicity. Monoclonal antibodies account for the majority of the recombinant protein market. chronic kidney disease (CKD) drugs (diabetes, cancer, cardiovascular disease, and others) will be the seventh biggest cause of death worldwide by 2030, according to the World Health Organization (WHO). This will fuel the expansion of the prokaryotic recombinant protein market because of its superior benefits and low side effects in treating chronic and autoimmune disorders. In terms of application, the global recombinant proteins market can be divided into Research Applications, Therapeutic Use, and Biotechnology Industry. The Therapeutic Use segment is anticipated to grow at a significant CAGR over the forecast years owing to recombinant protein-containing products used to treat diseases such as diabetes, cancer, and inflammatory diseases. An increase in the incidence of such diseases is likely to increase the demand for new treatment options. According to International Diabetes Federation, in 2019, approx. 463 million adults (20-79 years) were living with diabetes, and this value is projected to reach 700 million by 2045. Rising demand for therapeutics and the increasing use of recombinant proteins in treating diseases such as hemophilia are anticipated to positively influence the recombinant protein therapeutics market over the years to come.
Recombinant Proteins Market Key Developments:
- In March 2022, Fujifilm Corporation has acquired Shenandoah Biotechnology, Inc., one of the leading manufacturers of recombinant proteins.
- In January 2022, Thermo Fisher Scientific Inc. acquired PeproTech, Inc., one of the leading developers and manufacturers of recombinant proteins, for a total cash purchase price of approximately USD 1.85 billion.
Recombinant Proteins Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
3.1%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Recombinant Proteins Market Dynamics
Due to protracted research and approval procedures, the R&D sector has always remained capital-intensive. Governments see R&D as essential to a country's progress, international competitiveness, and public benefit. Due to which, R&D spending and funding have steadily increased. The 2019 Global R&D Funding Forecast predicts that global life science R&D investment will increase by 3.6% to USD 2.3 trillion by 2019. While the industry is the primary source of R&D financing, academia is also important because research articles are written by academics.
North America Got Significant Share
Recombinant Proteins Market Regional Analysis
The Recombinant Proteins market in North America is likely to hold the highest revenue share in 2022. The trend is expected over the forecast period due to the increasing expenditure on research, healthcare infrastructure, and several major market players. Chronic diseases across the region create a huge demand for recombinant protein therapies, as recombinant proteins are among the proven solutions for treating such diseases. Further, Asia Pacific held highest CAGR during the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Recombinant Proteins Market Segmentation
By Product
By Application
- Research Application
- Therapeutic Use
- Biotechnology Industry
By Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
LOCATION
Geography
Frequently Asked Questions
The global recombinant proteins market size is expected to be worth USD 1,926.1 million in 2022
Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Novo Nordisk A/S, Eli Lilly and Company., Merck KGaA, Abcam PLC, Amgen Inc., Sanofi SA, and Enzo Life Sciences, Inc are the key players in the market
Market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies, growing industry-academia collaborations, and the patent expiry of biologics.
| 1. Executive Summary |
| 2. Global Recombinant Proteins Market Introduction |
| 2.1.Global Recombinant Proteins Market - Taxonomy |
| 2.2.Global Recombinant Proteins Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Disease Type |
| 2.2.3.End Users |
| 2.2.4.Region |
| 3. Global Recombinant Proteins Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Recombinant Proteins Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Recombinant Proteins Market By Product Type , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Hormone |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Growth Factor |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Cytokines |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Enzymes |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Recombinant Proteins Market By Disease Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Research Application |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Therapeutic Use |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Biotechnology Industry |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Recombinant Proteins Market By End Users, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. The Asia Pacific |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. MEA |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. Global Recombinant Proteins Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Recombinant Proteins Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Hormone |
| 9.1.2.Growth Factor |
| 9.1.3.Cytokines |
| 9.1.4.Enzymes |
| 9.1.5.Others |
| 9.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Research Application |
| 9.2.2.Therapeutic Use |
| 9.2.3.Biotechnology Industry |
| 9.3. End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.North America |
| 9.3.2.Europe |
| 9.3.3.The Asia Pacific |
| 9.3.4.Latin America |
| 9.3.5.MEA |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Recombinant Proteins Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Hormone |
| 10.1.2.Growth Factor |
| 10.1.3.Cytokines |
| 10.1.4.Enzymes |
| 10.1.5.Others |
| 10.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Research Application |
| 10.2.2.Therapeutic Use |
| 10.2.3.Biotechnology Industry |
| 10.3. End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.North America |
| 10.3.2.Europe |
| 10.3.3.The Asia Pacific |
| 10.3.4.Latin America |
| 10.3.5.MEA |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11. Asia Pacific (APAC) Recombinant Proteins Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Hormone |
| 11.1.2.Growth Factor |
| 11.1.3.Cytokines |
| 11.1.4.Enzymes |
| 11.1.5.Others |
| 11.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Research Application |
| 11.2.2.Therapeutic Use |
| 11.2.3.Biotechnology Industry |
| 11.3. End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.North America |
| 11.3.2.Europe |
| 11.3.3.The Asia Pacific |
| 11.3.4.Latin America |
| 11.3.5.MEA |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12. Middle East and Africa (MEA) Recombinant Proteins Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Hormone |
| 12.1.2.Growth Factor |
| 12.1.3.Cytokines |
| 12.1.4.Enzymes |
| 12.1.5.Others |
| 12.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Research Application |
| 12.2.2.Therapeutic Use |
| 12.2.3.Biotechnology Industry |
| 12.3. End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.North America |
| 12.3.2.Europe |
| 12.3.3.The Asia Pacific |
| 12.3.4.Latin America |
| 12.3.5.MEA |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13. Latin America Recombinant Proteins Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Hormone |
| 13.1.2.Growth Factor |
| 13.1.3.Cytokines |
| 13.1.4.Enzymes |
| 13.1.5.Others |
| 13.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Research Application |
| 13.2.2.Therapeutic Use |
| 13.2.3.Biotechnology Industry |
| 13.3. End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.North America |
| 13.3.2.Europe |
| 13.3.3.The Asia Pacific |
| 13.3.4.Latin America |
| 13.3.5.MEA |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Bio-Rad Laboratories, Inc., |
| 14.2.2.Thermo Fisher Scientific, Inc. |
| 14.2.3.Novo Nordisk A/S |
| 14.2.4.Eli Lilly and Company. |
| 14.2.5. Merck KGaA |
| 14.2.6.Abcam PLC |
| 14.2.7.Amgen Inc. |
| 14.2.8.Sanofi SA |
| 14.2.9.Enzo Life Sciences, Inc |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Bio-Rad Laboratories, Inc.,
- Thermo Fisher Scientific, Inc.
- Novo Nordisk A/S
- Eli Lilly and Company.
- Merck KGaA
- Abcam PLC
- Amgen Inc.
- Sanofi SA
- Enzo Life Sciences, Inc